Cargando…

Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis

BACKGROUND: Fibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but analysis is challenging due to their ordered but non-numeric nature, infrequent measurement, misclassification, and unknown infection times. METHODS: We used a non-Markov multistate model, accounting...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacchetti, Peter, Boylan, Ross, Astemborski, Jacquie, Shen, Hui, Mehta, Shruti H., Thomas, David L., Terrault, Norah A., Monto, Alexander
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103523/
https://www.ncbi.nlm.nih.gov/pubmed/21637766
http://dx.doi.org/10.1371/journal.pone.0020104
_version_ 1782204533333557248
author Bacchetti, Peter
Boylan, Ross
Astemborski, Jacquie
Shen, Hui
Mehta, Shruti H.
Thomas, David L.
Terrault, Norah A.
Monto, Alexander
author_facet Bacchetti, Peter
Boylan, Ross
Astemborski, Jacquie
Shen, Hui
Mehta, Shruti H.
Thomas, David L.
Terrault, Norah A.
Monto, Alexander
author_sort Bacchetti, Peter
collection PubMed
description BACKGROUND: Fibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but analysis is challenging due to their ordered but non-numeric nature, infrequent measurement, misclassification, and unknown infection times. METHODS: We used a non-Markov multistate model, accounting for misclassification, with multiple imputation of unknown infection times, applied to 1062 participants of whom 159 had multiple biopsies. Odds ratios (OR) quantified the estimated effects of covariates on progression risk at any given time. RESULTS: Models estimated that progression risk decreased the more time participants had already spent in the current stage, African American race was protective (OR 0.75, 95% confidence interval 0.60 to 0.95, p = 0.018), and older current age increased risk (OR 1.33 per decade, 95% confidence interval 1.15 to 1.54, p = 0.0002). When controlled for current age, older age at infection did not appear to increase risk (OR 0.92 per decade, 95% confidence interval 0.47 to 1.79, p = 0.80). There was a suggestion that co-infection with human immunodeficiency virus increased risk of progression in the era of highly active antiretroviral treatment beginning in 1996 (OR 2.1, 95% confidence interval 0.97 to 4.4, p = 0.059). Other examined risk factors may influence progression risk, but evidence for or against this was weak due to wide confidence intervals. The main results were essentially unchanged using different assumed misclassification rates or imputation of age of infection. DISCUSSION: The analysis avoided problems inherent in simpler methods, supported the previously suspected protective effect of African American race, and suggested that current age rather than age of infection increases risk. Decreasing risk of progression with longer time already spent in a stage was also previously found for post-transplant progression. This could reflect varying disease activity, with recent progression indicating active disease and high risk, while longer time already spent in a stage indicates quiescent disease and low risk.
format Text
id pubmed-3103523
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31035232011-06-02 Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis Bacchetti, Peter Boylan, Ross Astemborski, Jacquie Shen, Hui Mehta, Shruti H. Thomas, David L. Terrault, Norah A. Monto, Alexander PLoS One Research Article BACKGROUND: Fibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but analysis is challenging due to their ordered but non-numeric nature, infrequent measurement, misclassification, and unknown infection times. METHODS: We used a non-Markov multistate model, accounting for misclassification, with multiple imputation of unknown infection times, applied to 1062 participants of whom 159 had multiple biopsies. Odds ratios (OR) quantified the estimated effects of covariates on progression risk at any given time. RESULTS: Models estimated that progression risk decreased the more time participants had already spent in the current stage, African American race was protective (OR 0.75, 95% confidence interval 0.60 to 0.95, p = 0.018), and older current age increased risk (OR 1.33 per decade, 95% confidence interval 1.15 to 1.54, p = 0.0002). When controlled for current age, older age at infection did not appear to increase risk (OR 0.92 per decade, 95% confidence interval 0.47 to 1.79, p = 0.80). There was a suggestion that co-infection with human immunodeficiency virus increased risk of progression in the era of highly active antiretroviral treatment beginning in 1996 (OR 2.1, 95% confidence interval 0.97 to 4.4, p = 0.059). Other examined risk factors may influence progression risk, but evidence for or against this was weak due to wide confidence intervals. The main results were essentially unchanged using different assumed misclassification rates or imputation of age of infection. DISCUSSION: The analysis avoided problems inherent in simpler methods, supported the previously suspected protective effect of African American race, and suggested that current age rather than age of infection increases risk. Decreasing risk of progression with longer time already spent in a stage was also previously found for post-transplant progression. This could reflect varying disease activity, with recent progression indicating active disease and high risk, while longer time already spent in a stage indicates quiescent disease and low risk. Public Library of Science 2011-05-27 /pmc/articles/PMC3103523/ /pubmed/21637766 http://dx.doi.org/10.1371/journal.pone.0020104 Text en Bacchetti et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bacchetti, Peter
Boylan, Ross
Astemborski, Jacquie
Shen, Hui
Mehta, Shruti H.
Thomas, David L.
Terrault, Norah A.
Monto, Alexander
Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis
title Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis
title_full Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis
title_fullStr Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis
title_full_unstemmed Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis
title_short Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis
title_sort progression of biopsy-measured liver fibrosis in untreated patients with hepatitis c infection: non-markov multistate model analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103523/
https://www.ncbi.nlm.nih.gov/pubmed/21637766
http://dx.doi.org/10.1371/journal.pone.0020104
work_keys_str_mv AT bacchettipeter progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis
AT boylanross progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis
AT astemborskijacquie progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis
AT shenhui progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis
AT mehtashrutih progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis
AT thomasdavidl progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis
AT terraultnoraha progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis
AT montoalexander progressionofbiopsymeasuredliverfibrosisinuntreatedpatientswithhepatitiscinfectionnonmarkovmultistatemodelanalysis